🔗 Visit the ClinicalTrials.gov page for NCT02364609
| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | Checkpoint inhibitors in lung cancer: latest developments and clinical potential. | Ther Adv Med Oncol | 2016 | 0.96 |
| 2 | Targeted therapies and immunotherapy in non-small-cell lung cancer. | Ecancermedicalscience | 2016 | 0.82 |
| 3 | Mutation testing for directing upfront targeted therapy and post-progression combination therapy strategies in lung adenocarcinoma. | Expert Rev Mol Diagn | 2016 | 0.80 |
| 4 | Recent Advances in Immunotherapy in Metastatic NSCLC. | Front Oncol | 2016 | 0.79 |
| 5 | Combining targeted therapy with immunotherapy. Can 1+1 equal more than 2? | Semin Immunol | 2016 | 0.78 |